{
}
UBS has maintained a "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton highlighted current prescription trends in the U.S. for the GLP-1 active ingredient, known for its appetite-suppressing effects.
Danske Bank A/S has initiated a share buy-back programme totaling DKK 5 billion, aiming to repurchase up to 45 million shares from 10 February 2025 to 30 January 2026. In week 13, the bank acquired 974,233 shares, bringing the total to 1,306,333 shares, representing 0.152% of its share capital.
Novo Nordisk's shares have dropped over 20% this year, primarily due to disappointing results for its weight loss drug CagriSema and concerns about Wegovy's market performance against Eli Lilly's Zepbound. Despite this, UBS maintains a "buy" rating with a target price of 750 DKK, suggesting a potential 56% upside. Wall Street remains divided, with half of analysts recommending a buy and the other half advising to hold, but no sell ratings are present.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns, influenced by current trends in weight loss drugs, particularly GLP-1. Analyst Jo Walton noted growth for Eli Lilly's Zepbound, while other competitors are seeing declines.
Danske Bank A/S, Denmark's leading bank, operates in four main areas: retail banking, market and investment banking, insurance through Danica Pension, and asset management. By the end of 2024, the bank is expected to manage DKK 1,173.8 billion in current deposits and DKK 1,074.8 billion in current loans, reflecting a delayed recovery in its EPS forecasts.
Goldman Sachs has initiated coverage on Royal Unibrew with a Buy rating and a price target of DKK 630, reflecting an 18% upside. The firm projects a robust EBIT CAGR of 10.4% from FY25 to FY27, anticipating a recovery in EBIT margins to 15.5% by 2027 as the company enhances efficiencies post-acquisitions. This outlook is more optimistic than the Visible Alpha Consensus Data, with estimates for EBIT and EPS 2% to 6% higher.
Danske Bank A/S has initiated a share buy-back programme totaling DKK 5 billion, aiming to repurchase up to 45 million shares from 10 February 2025 to 30 January 2026. In week 12, the bank acquired 207,100 shares, bringing the total to 332,100 shares, representing 0.039% of its share capital.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted disappointing growth in the US for the GLP-1 weight loss drug Wegovy in the first quarter, indicating that promotional efforts may not have been effective and that the company has lost market share among new patients.
Danske Bank has announced an increase in its dividend to DKK14.70, set to be paid on March 25, yielding 7.7%. Despite a history of dividend instability, the bank maintains a payout ratio of 60% and has shown strong earnings growth, though analysts forecast a slight decline in earnings per share over the next three years. Overall, while the dividend is being raised, concerns about its sustainability remain, suggesting investors may want to consider other income opportunities.
Danske Bank A/S, Denmark's leading bank, operates in retail banking, market and investment banking, insurance, and asset management. By the end of 2024, it managed DKK 1,173.8 billion in current deposits and DKK 1,074.8 billion in current loans. The bank anticipates the Bank of England will cut rates in May, maintaining a 'gradual' approach.
Danish Krone
Currency
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for novo nordisk with target price of 750 crowns
22:34 31.03.2025
danske bank completes week 13 of share buyback program with significant transactions
10:06 31.03.2025
ubs predicts over 50 percent recovery for novo nordisk shares
19:30 28.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
16:06 28.03.2025
Danske Bank faces delayed recovery as EPS forecasts are adjusted
14:17 28.03.2025
Goldman Sachs initiates buy rating for Royal Unibrew with DKK 630 target
08:51 27.03.2025
danske bank completes week 12 of share buyback program with significant transactions
10:00 24.03.2025
ubs maintains buy rating for novo nordisk despite disappointing wegovy growth
18:16 21.03.2025
Danske Bank raises dividend to DKK14.70 amid stable earnings outlook
13:59 21.03.2025
danske bank anticipates bank of england rate cuts in may
12:09 21.03.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Central Bank Actions
GDP Growth & Recession Forecasts
Global Trade Developments
Market Analysis and Predictions
Industry Mergers & Acquisitions
Financial Scams and Security
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Barclays PLC
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
Amazon.com, Inc.
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Turkish Lira
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
People: